rhamnopyranose | 97466-79-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: rhamnopyranose
• 英文别名: fucose；L-6-deoxy-galactose；β-L-6-deoxy-galactopyranose；α,β-L-Fucose；α-L-Fucopyranose；β-L-Fucopyranose；6-Deoxy-Hexose；6-methyloxane-2,3,4,5-tetrol
• CAS: 97466-79-0
• 化学式: C₆H₁₂O₅
• mdl: MFCD00066688
• 分子量: 164.158
• InChiKey: SHZGCJCMOBCMKK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.1
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  90.2
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  rhamnopyranose 在 吡啶 、 L-半胱氨酸甲酯盐酸盐 作用下， 反应 2.0h， 生成 L-rhamnopyranose
  参考文献：
  名称：

  Dokdolipids AC，来自海洋的放线菌Actinoalloteichus hymeniacidonis的羟基化鼠李糖脂。

  摘要：

  从海洋放线放线菌Actinoalloteichus hymeniacidonis中获得了三种新的羟基化鼠李糖脂，即dokdolipids AC（1-3），其是从韩国独岛岛沿岸收集的沉积物样品中分离出来的。在1D和2D NMR和质谱数据分析的基础上阐明了分离出的化合物的结构。使用改良的Mosher方法和比旋转值以及酸水解，化学衍生化和后续的HPLC分析来确定其糖基部分的绝对构型。评估了所有新化合物对六种癌细胞系HCT-15，NUGC-3，NCI-H23，ACHN，PC-3和MDA-MB-231的细胞毒性。

  DOI：

  10.3390/md17040237
• 作为产物：
  描述：

  4'-methoxy-5,7,3',5'-tetrahydroxyflavanone-3-O-rhamnopyranosyl-(1→3)-rhamnopyranoside 在 盐酸 作用下， 以 甲醇 为溶剂， 生成 rhamnopyranose
  参考文献：
  名称：

  Antihepatotoxic, nephroprotective, and antioxidant activities of phenolic compounds from Satureja macrostema leaves against carbon tetrachloride-induced hepatic damage in mice

  摘要：

  Satureja macrostema (SM) is used with culinary and medicinal purposes. Methanol extract from SM was investigated for its phenolic content, antioxidant, hepatoprotective, and kidney protective activities. Liver and kidney damage were induced in rats with CCl4. Hepatoprotective efficacy was measured by the activity of aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, total bilirubin, cholesterol, high density lipoprotein and total protein, and lipid peroxidation. Kidney function was evaluated by measuring plasma urea and creatinine. Antioxidant activity was evaluated by measuring blood glutathione content, superoxide dismutase and catalase activities, and malondialdehyde equivalent; their activity was comparable to that of silymarin, a well-known hepatoprotective agent. Methanol extracts of S. macrostema showed potent antioxidant, kidney protective, and hepatoprotective activities; in-depth chromatographic investigation resulted in the identification of six new flavonoid glycosides: 5-hydroxy-3,6,4'-trimethoxyflavonol-7-C-alpha-l-rhamnopyranosyl-(1 -> 3)-beta-d-glucopyranoside (2), 4'-methoxy-5,7,3',5'-tetra-hydroxyflavanone-3-O-beta-d-rhamnopyranosyl-(1 -> 2)-beta-d-rhamnopyranoside (3), 5,4'-dimethoxy-7,3',5'-trihydroxyflavanone-3-O-beta-d-rhamnopyranoside (4), 5,3',4',5'-tetrahydroxyflavanone-7-O-beta-d-rhamnopyranoside (5), 5,3',4',5'-tetramethoxyflavanone-7-O-beta-d-rhamnopyranoside (6), and 5,4'-dimethoxy-3'-hydroxyflavone-7-beta-d-rhamnopyranoside (8) along with three known compounds: 5-hydroxy-7,4'-dimethoxyflavone (1), prunin (7), and diosmin (9) that were isolated. Structural elucidation of the new compounds was established based on the spectral data. The present study revealed that S. macrostema leaves have a significant radical scavenging and hepatoprotective activity.

  DOI：

  10.1007/s00044-012-0176-x

文献信息

• [EN] COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS<br/>[FR] COMPOSÉS ET MÉTHODES POUR LE TRAITEMENT D'INFECTIONS BACTÉRIENNES
  申请人：CIDARA THERAPEUTICS INC

  公开号：WO2018006063A1

  公开（公告）日：2018-01-04

  Compositions and methods for the treatment of bacterial infections include compounds containing dimers of cyclic heptapeptides conjugated to one or more monosaccharide or oligosaccharide moieties. In particular, compounds can be used in the treatment of bacterial infections caused by Gram-negative bacteria.

  用于治疗细菌感染的组合物和方法包括含有环七肽二聚体与一个或多个单糖或寡糖基团结合的化合物。特别是，这些化合物可用于治疗由革兰氏阴性细菌引起的细菌感染。
• CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES
  申请人：Alnylam Pharmaceuticals, Inc.

  公开号：US20160051691A1

  公开（公告）日：2016-02-25

  The present invention provides iRNA agents comprising at least one subunit of the formula (I): wherein: A and B are each independently for each occurrence O, N(R N ) or S; X and Y are each independently for each occurrence H, OH, a hydroxyl protecting group, a phosphate group, a phosphodiester group, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, —P(Z′)(Z″)O-nucleoside, —P(Z′)(Z″)O-oligonucleotide, a lipid, a PEG, a steroid, a lipophile, a polymer, —P(Z′)(Z″)O-Linker-OP(Z′″)(Z″″)O-oligonucleotide, a nucleotide, an oligonucleotide, —P(Z′)(Z″)-formula(I), —P(Z′)(Z″)— or -Linker-R; R is L G , -Linker-L G , or has the structure shown below: L G is independently for each occurrence a carbohydrate, e.g., monosaccharide, disaccharide, trisaccharide, tetrasaccharide, oligosaccharide, polysaccharide; R N is independently for each occurrence H, methyl, ethyl, propyl, isopropyl, butyl, or benzyl; and Z′, Z″, Z′″ and Z″″ are each independently for each occurrence O or S.

  本发明提供了包含至少一个式(I)的亚单位的iRNA试剂： 其中： A和B分别独立于每次出现O、N(RN)或S； X和Y分别独立于每次出现H、OH、一个羟基保护基团、一个磷酸基团、一个磷酸二酯基团、一个活化磷酸基团、一个活化亚磷酸基团、一个磷酰胺基团、一个固相支持、-P(Z')(Z″)O-核苷、-P(Z')(Z″)O-寡核苷酸、一个脂质、一个PEG、一个类固醇、一个亲脂物质、一个聚合物、-P(Z')(Z″)O-连接子-OP(Z′″)(Z″″)O-寡核苷酸、一个核苷酸、一个寡核苷酸、-P(Z')(Z″)-式(I)、-P(Z')(Z″)-或-连接子-R； R是LG、-连接子-LG，或具有下面所示结构： LG独立于每次出现的是一种碳水化合物，例如，单糖、双糖、三糖、四糖、寡糖、多糖； RN独立于每次出现的是H、甲基、乙基、丙基、异丙基、丁基或苄基； Z'、Z″、Z′″和Z″″分别独立于每次出现的是O或S。
• [EN] COMPOSITIONS AND METHODS FOR TARGETING METASTATIC TUMORS USING MULTIVALENT LIGAND-LINKED CARBOHYDRATE POLYMERS<br/>[FR] COMPOSITIONS ET METHODES PERMETTANT DE CIBLER DES TUMEURS METASTATIQUES A L'AIDE DE POLYMERES MULTIVALENTS CARBOHYDRATES LIES A UN LIGAND
  申请人：PRO PHARMACEUTICALS INC

  公开号：WO2005092097A1

  公开（公告）日：2005-10-06

  Disclosed herein are compositions comprising a drug linked to a multivalent ligand polysaccharide and the use of this composition in the prevention and treatment of cancer. In one aspect, the polysaccharide is obtained by physical and chemical treatment of naturally occurring polymers or semi synthetic polymers which are bridged specifically with one or more anti-cancer chemotherapeutic agents. Another aspect is directed to the effective delivery of the polysaccharide together with the chemotherapeutic agent to diseased tissue including cancerous tissue.

  本文披露了包含药物与多价配体多糖相连的组合物，以及该组合物在预防和治疗癌症中的用途。在一个方面，该多糖是通过对天然聚合物或半合成聚合物进行物理和化学处理获得的，这些聚合物特异地与一个或多个抗癌化疗药物相桥接。另一个方面涉及将多糖与化疗药物有效地输送到包括癌组织在内的患病组织。
• Determination of the absolute configuration of monosaccharides by a colour change in a chiral cholesteric liquid crystal system
  作者：Tony D. James、Takaaki Harada、Seiji Shinkai

  DOI：10.1039/c39930000857

  日期：——

  Cholesterylboronic acid complexes of monosaccharides alter the colour of a composite chiral cholesteric liquid crystal membrane, the direction of the colour change is indicative of the absolute configuration of the monosaccharide.

  单糖的胆甾醇硼酸复合物改变复合手性胆甾型液晶膜的颜色，颜色变化的方向指示单糖的绝对构型。
• Medicament containing a sulfopyranosylacylglycerol derivative
  申请人：TOYO SUISAN KAISHA, LTD.

  公开号：US20020028776A1

  公开（公告）日：2002-03-07

  A medicament containing at least one compound selected from the group consisting of compounds represented by General formula (1): 1 wherein R 101 represents an acyl residue of an unsaturated higher fatty acid, and R 102 represents a hydrogen atom or an acyl residue of an unsaturated higher fatty acid, and pharmaceutically acceptable salts thereof, as an active ingredient.

  包含至少一种从以下组中选择的化合物的药物：由通用公式(1)表示的化合物组1其中，R101代表不饱和高级脂肪酸的酰基残基，R102代表氢原子或不饱和高级脂肪酸的酰基残基，以及药用可接受的盐作为有效成分。

表征谱图